edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Mendus
Mendus is an immuno-oncology company focused on immunotherapies for myeloid blood cancers. The company’s leading clinical candidate is vididencel, an off-the-shelf cellular immunotherapy that has demonstrated durable clinical remissions in acute myeloid leukemia (AML). Mendus is developing vididencel as a broadly applicable post-remission treatment in AML and has expanded indications to include chronic myeloid leukemia (CML). Earlier-stage programs focusing on ovarian cancer and other solid tumors.
Mendus — 3 videos in collection
In this video, we speak with Dr Tariq Mughal, chief medical officer at Mendus. We discuss Tariq’s interest in the blood cancer space before moving on to Mendus’s lead programme in acute myeloid leukaemia (AML) maintenance, as well as the potential to expand vididencel’s application to other indications.
Listen on your preferred podcast player below:
About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.
Get access to the very latest content matched to your personal investment style.